Table 1 Demographic and clinical characteristics of the studies included in the meta-analysis.

From: Disrupted local functional connectivity in schizophrenia: An updated and extended meta-analysis

Study

Sample size (female)

Mean age (y)

Education (y)

Age at onset (y)

Duration (m)

PANSS

Medication (%)

First episode

SZ

HC

SZ

HC

SZ

HC

Total

Positive

Negative

Bai et al. (2016)

17 (3)

17 (3)

26.00

28.71

10.59

13.65

NA

40.29

82.06

15.29

24.88

Drug free

Partial

Cui et al. (2016)a

17 (7)

19 (9)

21.24

23.79

13.71

14.74

NA

6.51

106.24

31.12

25.53

Drug naive

Yes

Cui et al. (2016)a

15 (7)

19 (9)

22.53

23.79

13.40

14.74

NA

10.20

88.07

17.93

22.73

Drug naive

Yes

Gao et al. (2015)

14 (5)

14 (5)

33.20

34.90

11.70

11.30

NA

9.20

74.10

16.40

22.60

100

No

Gao et al. (2018)a

17 (7)

29 (13)

31.24

32.73

12.24

14.28

17.24

14.00

97.76

27.53

21.05

100

No

Gao et al. (2018)a

17 (8)

29 (13)

36.82

32.73

13.76

14.28

29.18

7.88

37.29

9.53

8.41

100

No

Gao et al. (2020)

57 (37)

50 (27)

31.63

28.38

12.86

15.64

NA

2.52

91.84

26.39

20.68

Drug naive

No

Gou et al. (2018)

28 (12)

21 (7)

23.90

28.80

12.90

12.90

NA

15.10

85.70

17.80

21.00

100

No

Hu et al. (2016)

42 (15)

38 (13)

24.86

24.76

10.48

11.05

NA

8.38

91.90

25.60

18.17

Drug naive

Yes

Jin et al. (2021)

23 (12)

24 (12)

31.74

30.92

12.57

14.04

NA

NA

NA

NA

NA

Drug naive

Yes

Liu et al. (2006)

18 (9)

18 (9)

23.67

24.44

14.11

15.28

NA

26.83

80.39

NA

NA

Drug free

No

Liu et al. (2016)

27 (12)

27 (9)

25.44

27.44

12.30

12.96

NA

18.32

85.78

21.56

23.15

44

No

Lyu et al. (2021)

32 (17)

27 (17)

16.75

16.40

10.19

10.11

NA

9.19

79.44

22.75

16.97

Drug naive

Yes

Shan et al. (2021)

39 (12)

20 (6)

24.36

25.70

11.13

12.75

NA

5.00

103.90

23.82

27.28

Drug free

No

Wang et al. (2017)

48 (27)

31 (17)

15.79

15.42

8.88

8.44

NA

5.35

75.10

21.50

17.92

Drug naive

No

Yan et al. (2020)

69 (19)

74 (29)

24.22

26.27

13.23

14.69

NA

13.74

84.19

24.42

17.58

Drug naive

Yes

Yang et al. (2021)

37 (28)

39 (30)

39.70

40.94

10.35

9.56

22.70

204.00

76.00

13.60

23.90

100

No

Yu et al. (2013)

69 (36)

62 (NA)

31.70

29.90

14.20

15.30

NA

7.10

52.90

12.10

13.40

100

No

Yu et al. (2021)

22 (11)

60 (22)

33.41

32.87

10.77

14.02

NA

15.48

93.50

27.18

19.82

Drug naive

No

Zhao et al. (2019)

44 (13)

26 (9)

23.70

22.60

12.80

13.90

NA

12.00

102.00

15.30

24.70

Drug naive

Yes

BrainGluSchi

58 (6)

77 (27)

35.26

38.86

NA

NA

20.17

181.08

61.02b (n = 53)

16.36b (n = 56)

15.67b (n = 55)

90

NA

COBRE

71 (13)

84 (23)

36.62

38.87

NA

NA

21.12b (n = 69)

182.76b (n = 69)

59.23b (n = 69)

15.15

15.31b (n = 70)

97

NA

NMorphCH

34 (7)

33 (16)

33.94

29.33

13.00b (n = 26)

16.23b (n = 22)

18.75b (n = 25)

188.76b (n = 25)

NA

NA

NA

NA

NA

  1. Note: aThe study consisted of two subgroups, and we treated it as two separate datasets. bThe information of some participants was not available, and the number of samples with which were provided in parentheses.
  2. Abbreviations: HC healthy control; m month; NA not available; PANSS Positive and Negative Syndrome Scale; SZ schizophrenia; y year.